

Merck strikes deal for global access to COVID drug

27 October 2021, by Robin Millard



The global Medicines Patent Pool said it had signed a voluntary licensing agreement with Merck to facilitate affordable worldwide access for its investigational oral antiviral medicine molnupiravir.

US drugmaker Merck & Co. on Wednesday announced a deal that could see generic versions of its COVID-19 medication widely distributed in poorer countries, in a first during the pandemic.

The global Medicines Patent Pool (MPP) said it had signed a voluntary licensing agreement with Merck to facilitate affordable worldwide access for its investigational oral antiviral medicine molnupiravir.

Subject to regulatory approval, the deal will help create broad access to molnupiravir in 105 low- and middle-income countries.

The US and European Union medicines regulators are reviewing the drug.

Antivirals like molnupiravir work by decreasing the ability of a virus to replicate, thereby slowing down the disease.

Given to patients within days of a positive test, the treatment halves the risk of hospitalisation, according to a clinical trial conducted by Merck, also called MSD outside the United States.

Merck's deal with MPP is "a positive step towards creating broader access to treatment as quickly as possible," the World Health Organization said in a statement.

But it urged the drugmaker to "provide data of clinical trials to WHO as soon as possible so the agency can evaluate the medicine for global use".

It also pressed Merck to "include other key countries in the scope of the agreement in the near future".



Antivirals like molnupiravir (capsules pictured in a handout photo obtained from Merck on May 26, 2021) work by decreasing the ability of a virus to replicate, thereby slowing down the disease.

The Geneva-based MPP is a United Nations-backed international organisation that works to facilitate the development of medicines for low- and middle-income nations.

Under the deal, Merck grants a licence to the MPP,

under which the organisation can then sub-licence to makers of generic drugs.

The deal means the drug's developers will not receive sales royalties while COVID-19 remains classified as a public health emergency of international concern (PHEIC) by the WHO.

A PHEIC is the highest alarm the WHO can sound and its emergency committee last week reconfirmed the pandemic's top-alert status.

Price not yet set

"The interim results for molnupiravir are compelling and we see this oral treatment candidate as a potentially important tool to help address the current health crisis," said MPP executive director Charles Gore.

Merck is jointly developing molnupiravir with Ridgeback Biotherapeutics.

The Miami-based company's chief executive Wendy Holman said the deal meant "quality-assured generic versions of molnupiravir can be developed and distributed quickly following regulatory authorisation".

The MPP was founded by Unitaid, which works on innovations to prevent, diagnose and treat major diseases in poorer countries.

Graphic on major drug strategies approved, under investigation or dismissed in the battle against Covid-19.

Molnupiravir prices have not yet been determined, but its simplicity, plus competition among generic manufacturers should mean low prices in the 105 poorer countries, said Unitaid spokesman Herve Verhoosel.

He said in countries with low vaccination rates, millions would need the drug to prevent progression to serious illness.

"We also need to see this licence followed by others as soon as possible for other key promising products expected to come out of the pipeline soon, for which we also need to ensure broad supply and affordability," Verhoosel added.

IP waiver call

While the search for vaccines has resulted in multiple products being approved for emergency use in the pandemic, the hunt for treatments for those who have already caught the disease has not been as fruitful.

The medical charity Doctors Without Borders (MSF) welcomed the announcement but said it did not go far enough.

"The licence excludes key upper-middle-income countries like Brazil and China from its territory, where there is strong, established capacity to produce and supply antiviral medicines," MSF senior policy advisor Yuanqiong Hu said.

"Furthermore, the licence contains an unacceptable clause undermining the rights to challenge patents on molnupiravir."

Hu said the agreement underlined the urgent need for a temporary waiver of intellectual property rights for all COVID-19 medicines, vaccines and tests.

Main drug strategies for Covid-19

Antivirals	Immunity boosters	Immune response modulators
<p>Act directly on the virus to stop or slow replication</p>	<p>Strengthen the immune system's ability to fight the virus</p>	<p>Work against inflammation and potential immune system overdrive</p>
<p>Major examples: Approved, under investigation or dismissed</p> <p>Molnupiravir US firm Merck has applied for emergency use authorisation of the oral drug in the US after promising test data</p> <p>Remdesivir and hydroxychloroquine Gained much attention early in the pandemic, but stopped being recommended by end of 2020</p>	<p>REGN-COV2: casirivimab and imdevimab antibody cocktail WHO recommendation for high risk patients since Sept 2021</p> <p>Ronapreve Monoclonal antibody combination, submitted for approval in the EU by Swiss firm Roche</p> <p>AZD7442 Maker AstraZeneca revealed positive results</p>	<p>Corticosteroids such as dexamethasone and hydrocortisone Recommended for severe cases since Sept 2020</p> <p>Tocilizumab and Sarilumab Arthritis drugs approved in July 2021 by the WHO</p>

Sources: newscientist.com/covid19treatmentguidelines.nih.gov/pharmaceutical-journal.com/medicalnewstoday.com AFP

© 2021 AFP

APA citation: Merck strikes deal for global access to COVID drug (2021, October 27) retrieved 17 May 2022 from <https://medicalxpress.com/news/2021-10-merck-global-access-covid-drug.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.